Navigation Links
Elekta to Highlight Clinical and Safety Advantages of Gamma Knife Radiosurgery at 2013 AANS Meeting
Date:4/25/2013

NEW ORLEANS, April 25, 2013 /PRNewswire/ -- At the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting April 27-May 1 at the Ernest N. Morial Convention Center, Elekta (booth #2239) will spotlight the continuing preeminence of Gamma Knife® stereotactic radiosurgery (SRS) as the gold standard for treating benign and malignant brain tumors, plus other functional and vascular brain disorders.

"As the only radiosurgery device designed and dedicated to the brain, Leksell Gamma Knife has set the standard of safe and effective treatment of brain conditions," says Jay Hoey , Executive Vice President, Elekta North America . "Today, it remains the standard by which all other radiosurgery treatments are measured, treating more than 70,000 people a year with more than 800 scientific papers [studies with more than 30 patients] backing the technology.

"Gamma Knife surgery is an exceptional treatment choice for cases in which adjacent critical structures are at high risk of radiotoxicity, such as in the treatment of trigeminal neuralgia, residual meningiomas and acoustic neuroma," he adds. "For other intracranial targets such as multiple brain metastases, Leksell Gamma Knife provides less dose to normal brain tissues than other techniques."

Spotlight on patient safety and provider efficiency
Dedicated to intracranial stereotactic radiosurgery, Leksell Gamma Knife supports enhanced patient safety via the system's single-focused SRS design and simplicity-of-operation, which decrease the risk of mechanical and human error.

Typically capable of completing therapy in a single outpatient procedure, Gamma Knife surgery has also demonstrated significant efficiency advantages for providers as well. In comparison, Center for Medicare Services (CMS) 2011 claims data indicate that most patients receiving SRS delivered with a linear-accelerator require up to four outpatient procedures to complete their course of therapy.

Gamma Knife also will be featured in the Scientific Program of the AANS with results from two multicenter trials detailing the results of Gamma Knife in the treatment of benign tumors and hemangioblastomas, and two single center, large series reports on the use of Gamma Knife in vascular malformations. In addition, Gamma Knife is featured in several breakfast seminars and practical clinics, which will further clarify the role of the technology as an important adjunct to neurosurgery.

Additional Elekta solutions to be showcased at AANS include:

  • Leksell GammaPlan® 10, for optimal treatment planning for Gamma Knife radiosurgery
  • Elekta Neuromag® TRIUX, the most sophisticated magnetoencephalography (MEG) system available
  • Leksell Stereotactic System®, the preferred system for functional neurosurgery and biopsies
  • Leksell SurgiPlan® 10, for advanced, image-based neurosurgical planning

For further information, please contact:
Johan Andersson , Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com  
Time zone: CET: Central European Time 

Michelle Joiner , Director, Global Public Relations and Brand Management, Elekta 
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com 
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives. 

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.


'/>"/>
SOURCE Elekta
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy Adds The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
2. MD Anderson Cancer Center Acquires Two Elekta Versa HD Systems
3. Nucletron, an Elekta company, to Debut New Flexitron Brachytherapy Afterloading Platform at 2013 American Brachytherapy Society Meeting
4. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
5. U.K. Clinic Anticipating New Era of Radiotherapy Speed and Precision with Elektas New Versa HD System
6. Elektas Advanced Versa HD System to Begin Treating Cancer Patients at New Swiss Radiotherapy Clinic
7. Krebspatienten an neuem Schweizer Zentrum für Strahlentherapie werden mit Elektas fortschrittlichem Versa HD-System behandelt
8. Denmarks Odense University Hospital Orders Elektas New Versa HD Linear Accelerator for Radiotherapy Treatment of Patients with Cancer
9. Elekta Focuses on Clinical Workflows with MOSAIQ Oncology Information Management System at HIMSS13 Meeting
10. Banner MD Anderson Cancer Center Acquires Multiple Elekta Cancer Management Systems
11. Elektas New Radiation Oncology Technology to Shape the Future of Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 Interpace Diagnostics Group, Inc., (NASDAQ: ... diagnostic tests and pathology services for evaluating risks of ... dated January 13, 2017 from the NASDAQ Listing Qualifications ... the requirement of the NASDAQ Stock Market to maintain ... The letter noted that for the last ...
(Date:1/17/2017)... Research and Markets has announced the addition of the ... ... laparotomy sponges market to grow at a CAGR of 7.94% during ... 2016-2020, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:1/17/2017)... 2017 Tempus, a technology company focused ... Hospitals Seidman Cancer Center have joined together to ... advanced molecular analysis and clinical decision support tools ... providers. As part of the ... sequencing and analysis for ovarian and triple negative ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting ... Challenge , the Cradle to Cradle Products Innovation Institute has announced. , ... run through early 2018. The challenges are presented by the Institute in partnership with ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare company ... clinical study for its dental gel that shows significant reduction in plaque levels and ... triclosan. The study was conducted at the Beckman Laser Institute at UC Irvine and ...
(Date:1/17/2017)... ... , ... Many people make New Year’s resolutions or renew their commitment to better health with ... for people who want to kick off 2017 with better smiles. Dr. Mondavi is offering ... special offers include: , , A new patient package for just ...
(Date:1/16/2017)... ... ... California Southern University has named Dr. Steven Beazley University President. ... a core faculty member, teaching master’s and doctoral courses in the university’s School of ... where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also has ...
(Date:1/16/2017)... ... 2017 , ... Houston dentist, Dr. Behzad Nazari, announces that ... and financing for orthodontics for a limited time. Complimentary for a limited time, ... orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. Antoine Dental also ...
Breaking Medicine News(10 mins):